ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

EVFM Evofem Biosciences Inc

0.4782
0.00 (0.00%)
After Hours
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Evofem Biosciences Inc NASDAQ:EVFM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.4782 0.465 0.468 0 01:00:00

Evofem Biosciences to Report Second Quarter 2018 Results and Provide Corporate Update on August 2, 2018

19/07/2018 1:30pm

PR Newswire (US)


Evofem Biosciences (NASDAQ:EVFM)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Evofem Biosciences Charts.

SAN DIEGO, July 19, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, will hold a conference call to discuss financial results and business highlights for the quarter ended June 30, 2018, as follows:

Date

Thursday August 2, 2018

Time

11:00 a.m. EDT

Dial-in numbers

(866) 503-5561  (U.S. toll-free) or (253) 336-2965

Passcode

2086111

Webcast (live and archived)

www.evofem.com under "Investors" or click here

www.evofem.com

The teleconference replay will be available approximately two hours after completion through Tuesday, August 7, 2018, at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The replay access code is 2086111.  The archived webcast will be available via the aforementioned URLs. 

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem is leveraging its proprietary Multi-purpose Prevention Technology vaginal gel to develop product candidates for multiple indications, including contraception, the prevention of urogenital transmission of chlamydia and gonorrhea in women, and recurrent bacterial vaginosis. For more information regarding Evofem, please visit www.evofem.com.

Evofem Biosciences' Contact
Amy Raskopf
Investor Relations
araskopf@evofem.com
858-550-1900 x167

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-report-second-quarter-2018-results-and-provide-corporate-update-on-august-2-2018-300682789.html

SOURCE Evofem Biosciences, Inc.

Copyright 2018 PR Newswire

1 Year Evofem Biosciences Chart

1 Year Evofem Biosciences Chart

1 Month Evofem Biosciences Chart

1 Month Evofem Biosciences Chart

Your Recent History

Delayed Upgrade Clock